![\"\"](\"https:\/\/www.azuse.cloud\/wp-content\/uploads\/2021\/03\/leaf-300x277.jpg\")
<\/p>\n<\/p>\n
Todd South<\/strong><\/p>\n The first FDA-regulated, placebo-controlled, double-blind study on smoked cannabis among veterans with diagnosed PTSD revealed improvements among those receiving doses with higher levels of THC, an active component in the herbal drug.<\/p>\n Published March 17 in the journal PLOS ONE, the peer-reviewed paper compares results of PTSD treatment in three cannabis combinations, as well as a placebo control group.<\/p>\n The study, conducted by the Multidisciplinary Association for Psychedelic Studies, or MAPS, indicated levels of improvement among participants using smoked cannabis blends with a 9 percent THC concentration. Improvements were also found using samples containing 11 percent CBD, as well as a sample containing 8 percent THC and 8 percent CBD. A fourth group, which also reported improvements, used a placebo.<\/p>\n THC, or delta-9-tetrahydrocannabinol, is the intoxicating, or psychoactive, ingredient of cannabis strains that produce the euphoric \u201chigh\u201d effect. CBD, or cannabidiol, is one of the non-intoxicating cannabinoids in the cannabis plant. CBD-only products have been widely adopted in multiple states for medical, therapeutic and recreational uses.<\/p><\/blockquote>\n Promising treatments should be pursued. Read the entire article here: Military Times<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"